Regarding the latter, it is intriguing to notice that although all six CRC lines we studied fall into the group of good to strong sensitivity to clofazimine (Figure 1E), the distinction between the four “good” lines (HCT116, DLD1, SW620, LS174T) and the two “strong” lines (SW48 and HT29) may lie in the KRAS mutation status. This evidence concerns the gene KRAS and colorectal carcinoma.